Published in Blood on May 01, 2001
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Screening panels for detection of monoclonal gammopathies. Clin Chem (2009) 2.05
Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood (2006) 1.98
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol (2008) 1.54
Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis (2006) 1.45
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia (2012) 1.41
Appraisal of immunoglobulin free light chain as a marker of response. Blood (2008) 1.38
Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol (2010) 1.36
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. Leukemia (2012) 1.23
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood (2009) 1.15
Multiple myeloma. Curr Probl Cancer (2009) 1.04
Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia (2011) 1.03
Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol (2008) 1.00
Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol (2009) 0.98
Quantitative serum free light chain assay--analytical issues. Clin Biochem Rev (2009) 0.90
Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia (2015) 0.88
Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder. Am J Transplant (2012) 0.87
Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev (2009) 0.87
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. Am J Hematol (2010) 0.87
Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation (2013) 0.86
Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev (2009) 0.85
Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis. Clin Vaccine Immunol (2006) 0.85
Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant (2008) 0.83
Discovering the meaning of monoclonal gammopathy of undetermined significance: current knowledge, future challenges. Transl Med UniSa (2014) 0.82
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica (2015) 0.81
Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients. Blood (2009) 0.81
Using single protein biomarkers to predict health and disease in diverse patient populations: a new role for assessment of immunoglobulin free light chains. Mayo Clin Proc (2012) 0.80
Serum Free Light Chain Only Myeloma with Cytoplasmic IgM. Case Rep Hematol (2014) 0.80
Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions. Ther Adv Hematol (2013) 0.80
Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs (2011) 0.79
Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. Br J Haematol (2012) 0.79
Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma. PLoS One (2015) 0.77
Non-secretory multiple myeloma: from biology to clinical management. Onco Targets Ther (2016) 0.75
Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study. BMC Cancer (2007) 0.75
Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease. Int J Rheumatol (2013) 0.75
The value of serum immunoglobulin free light chain assessment in patients with monoclonal gammopathies and acute renal failure. Turk J Haematol (2012) 0.75
Immunoglobulin free light chains in adult atopic dermatitis patients do not correlate with disease severity. Clin Transl Allergy (2016) 0.75
Congestive heart failure: a case of protein misfolding. Hawaii J Med Public Health (2014) 0.75
Nonsecretory Multiple Myeloma and AL Amyloidosis Presenting with Nephrotic Range Proteinuria. Case Rep Nephrol (2015) 0.75
Oligo-secretory myeloma in a patient with ankylosing spondylitis. Rheumatol Int (2009) 0.75
Oligosecretory multiple myeloma: a case report. Blood Res (2016) 0.75
Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. Oncol Lett (2016) 0.75
Asymptomatic Multiple Myeloma Presenting as a Nodular Hepatic Lesion: A Case Report and Review of the Literature. Ochsner J (2015) 0.75
Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion. Clin Exp Immunol (2017) 0.75
Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem (2001) 3.94
Structure, function and properties of antibody binding sites. J Mol Biol (1991) 2.84
Serum free light chains for monitoring multiple myeloma. Br J Haematol (2004) 2.07
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet (1998) 2.06
Localisation of tumour deposits by external scanning after injection of radiolabelled anti-carcinoembryonic antigen. Br Med J (1980) 1.82
Low plasma C4 concentrations: association with microangiopathy in insulin dependent diabetes. Br Med J (Clin Res Ed) (1984) 1.82
A consolidated linkage map for rainbow trout (Oncorhynchus mykiss). Anim Genet (2003) 1.81
A study of plasma proteins in the sol phase of sputum from patients with chronic bronchitis. Thorax (1979) 1.79
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res (2001) 1.68
Properties of monoclonal antibodies to human immunoglobulin kappa and lambda chains. Immunology (1981) 1.65
Identification of susceptibility loci for insulin-dependent diabetes mellitus by trans-racial gene mapping. Nature (1989) 1.64
Effect of carbon dioxide in acute mountain sickness: a rediscovery. Lancet (1988) 1.64
Differential effects of cimetidine on theophylline metabolic pathways. Eur J Clin Pharmacol (1984) 1.60
Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol (2003) 1.55
Perceptions of children and community members concerning the circumstances of orphans in rural Zimbabwe. AIDS Care (1997) 1.54
Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol (1999) 1.47
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
A quantitative study of the distribution of IgG sub-classes in a group of normal human sera. J Immunol Methods (1975) 1.36
Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res (1989) 1.35
Controlling mouse pointer position using an infrared head-operated joystick. IEEE Trans Rehabil Eng (2000) 1.35
Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat Rev (1987) 1.31
The clinical assessment of acute mountain sickness. Q J Med (1985) 1.28
The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochem Pharmacol (1984) 1.27
Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab (2003) 1.24
The effect of acetazolamide on the proteinuria of altitude. Aviat Space Environ Med (1982) 1.23
Altitude insomnia: studies during an expedition to the Himalayas. Sleep (1988) 1.21
Supporting children in need through a community-based orphan visiting programme. AIDS Care (1996) 1.20
Limitations to the killing of tumours using radiolabelled antibodies. Br J Radiol (1987) 1.13
Improved tumour localisation using indium-111 labelled antibodies. Br Med J (Clin Res Ed) (1983) 1.12
Placental iodothyronine deiodinase expression in normal and growth-restricted human pregnancies. J Clin Endocrinol Metab (2003) 1.09
Effect of exercise on cerebral perfusion in humans at high altitude. J Appl Physiol (1985) (2005) 1.09
Methazolamide and acetazolamide in acute mountain sickness. Aviat Space Environ Med (1983) 1.09
Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet (1986) 1.09
Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia (2012) 1.08
Effect of acetazolamide on blood gases and 2,3 DPG during ascent and acclimatization to high altitude. Postgrad Med J (1987) 1.05
Detection of thyroid tumours using radio-labelled anti-thyroglobulin. Clin Endocrinol (Oxf) (1983) 1.05
Cloning and DNA sequence of amiC, a new gene regulating expression of the Pseudomonas aeruginosa aliphatic amidase, and purification of the amiC product. J Bacteriol (1991) 1.05
Explaining the unexpected abnormal results of biochemical profile investigations. Lancet (1974) 1.04
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia (2010) 1.03
Crystal structure of AmiC: the controller of transcription antitermination in the amidase operon of Pseudomonas aeruginosa. EMBO J (1994) 1.03
Ionizing Particle Evidence for the Molecular Weight of the Pneumococcus Transforming Principle. Proc Natl Acad Sci U S A (1952) 1.02
Phenotypes of the heavy chains of immunoglobulins in patients with diabetic microangiopathy: evidence for an immunogenetic predisposition. Br Med J (Clin Res Ed) (1986) 1.02
Preparation of a monospecific antiserum to thyroxine binding globulin for its quantitation by rocket immunoelectrophoresis. Clin Chim Acta (1976) 1.01
Mechanism of action of paracetamol protective agents in mice in vivo. Biochem Pharmacol (1984) 1.00
Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol (2000) 1.00
Blood lactate changes during exercise at high altitude. Postgrad Med J (1987) 0.99
The origin of proteinuria at high altitude. Postgrad Med J (1987) 0.98
The Environmental Symptoms Questionnaire in acute mountain sickness. Aviat Space Environ Med (1985) 0.98
Identification of susceptibility loci for type 1 (insulin-dependent) diabetes by trans-racial gene mapping. Diabetologia (1990) 0.97
Choleretic and cholestatic effects of infused bile salts in the rat. Experientia (1979) 0.95
Measurement of human serum IgE and IgA by reverse passive antiglobulin haemagglutination. Int Arch Allergy Appl Immunol (1981) 0.95
Trans-racial studies implicate HLA-DQ as a component of genetic susceptibility to type 1 (insulin-dependent) diabetes. Diabetologia (1988) 0.94
Excessive use of vancomycin: a successful intervention strategy at an academic medical center. Infect Control Hosp Epidemiol (2000) 0.94
Studies on the developmental expression of glutathione S-transferase isoenzymes in human heart and diaphragm. Biochim Biophys Acta (1987) 0.93
Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using immunoassays specific for free immunoglobulin light chains. Clin Lab (2003) 0.93
Cerebral blood flow in acute mountain sickness. J Appl Physiol (1985) (1990) 0.92
The amidase regulatory gene (amiR) of Pseudomonas aeruginosa. J Gen Microbiol (1987) 0.89
Estimation of the Stokes radii of serum proteins for a study of protein movement from blood to amniotic fluid. Biochim Biophys Acta (1976) 0.89
Improved radioimmunodetection of tumours using second antibody. Lancet (1983) 0.88
IgG-subclass concentrations in cord sera from premature, full term and small-for-dates babies. Eur J Pediatr (1977) 0.88
IgG subclasses in systemic lupus erythematosus and other autoimmune rheumatic diseases. Lupus (1992) 0.88
Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab (2004) 0.88
Radioimmunodetection of gastrointestinal neoplasms with antibodies to carcinoembryonic antigen. Cancer Res (1980) 0.87
An experiment in enzyme evolution. Studies with Pseudomonas aeruginosa amidase. Biosci Rep (1988) 0.87
Postulated reactive intermediates of NSAID's. Agents Actions Suppl (1985) 0.87
Localisation of malignant germ-cell tumours by external scanning after injection of radiolabelled anti-alpha-fetoprotein. Br Med J (Clin Res Ed) (1981) 0.87
Quantitation of vitronectin in serum: evaluation of its usefulness in routine clinical practice. J Clin Pathol (1993) 0.86
Birmingham Medical Research Expeditionary Society 1977 Expedition: serum and urine proteins during a high altitude trek. Postgrad Med J (1979) 0.86
Effect of whole-body hyperthermia on the disposition and metabolism of adriamycin in rabbits. Cancer Res (1978) 0.86
Relation of gene expression (allotypes) of the fourth component of complement to insulin dependent diabetes and its microangiopathic complications. Br Med J (Clin Res Ed) (1985) 0.85
The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients. Br J Cancer (1975) 0.85
IgA subclasses in sputum from patients with bronchiectasis. Respir Med (1990) 0.85
Case 2--1996. Anesthetic management of a patient with hemoglobin SS disease and mitral insufficiency for mitral valve repair. J Cardiothorac Vasc Anesth (1996) 0.85
Complementation analysis of the aliphatic amidase genes of Pseudomonas aeruginosa. J Gen Microbiol (1984) 0.85
Class II HLA DNA polymorphisms in type 1 (insulin-dependent) diabetic patients of north Indian origin. Diabetologia (1988) 0.85
Identification of the serum binding proteins for iron, zinc, cadmium, nickel, and calcium. Clin Chem (1983) 0.84
The detection of tritium-labeled ligands and their carrier proteins using a multiwire proportional counter. Anal Biochem (1982) 0.84
Propranolol binding to serum orosomucoid. Lancet (1979) 0.84
The HLA-D associations of type 1 (insulin-dependent) diabetes in Punjabi Asians in the United Kingdom. Diabetologia (1987) 0.84
Monoclonal antibodies for in-vivo localization. Lancet (1982) 0.83
Cancer-associated proteins in effusion fluids. J Clin Pathol (1977) 0.83
The impact of counselling on HIV-infected women in Zimbabwe. AIDS Care (1998) 0.82
Clinical evaluation of anti-alpha-fetoprotein radioimmunodetection. Br J Radiol (1986) 0.82
Improved methodology and precision using a straight base line technique for the quantitation of proteins by two dimensional immunoelectrophoresis. Clin Chim Acta (1975) 0.82
Lipid peroxidation and platelet activation in murine atherosclerosis. Circulation (2001) 0.82
Subclass typing of IgG paraproteins by immunofixation electrophoresis. Clin Chem (1995) 0.81
An arterio-venous study of serum alpha1-antitrypsin in patients with chronic bronchitis. Clin Chim Acta (1978) 0.81
Immunodetection of 11 beta-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization. Endocrinology (1997) 0.81
Low molecular weight proteinuria in insulin-dependent diabetes. Diabetes Res (1986) 0.81
The inter-relationship of thyroid hormones, vitamin A and their binding proteins following acute stress. Clin Endocrinol (Oxf) (1978) 0.81
HLA-DR and DQ DNA polymorphisms in subjects of Asian Indian and white Caucasian origin. Mol Immunol (1988) 0.81
Synthesis of two components of human complement, beta 1H and C3bINA, during fetal life. Acta Paediatr Scand (1981) 0.81
Hepatic cytochrome P-450-dependent metabolism and enzymatic conjugation of foreign compounds in vitamin A-deficient rats. Pharmacology (1980) 0.80
The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. Toxicol Appl Pharmacol (1979) 0.80
The inhibition of cathepsin B by plasma haptoglobin biochemistry (enzymes, metabolism). Experientia (1981) 0.80
Illusions of tumour killing using radiolabelled antibodies. Lancet (1986) 0.80